Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials

    NEXT STORY
    Teladoc Health Reports Second Quarter 2019 Results
    PREV STORY
    BioRestorative Therapies Signs $5.4 Million Financing with Institutional Investor
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Biosafety Cabinets Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Type ; End User ; and Geography

    author_avatar
    NASDAQ Market News

    ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting

    – Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping ...

    author_avatar
    NASDAQ Market News

    Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    author_avatar
    NASDAQ Market News